Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 107.53M -18.1% |
| Revenue (ttm) | n/a -70.0% |
| Net Income | -67.43M |
| EPS | -1.03 |
| Shares Out | 103.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,760,062 |
| Open | 0.961 |
| Previous Close | 0.986 |
| Day's Range | 0.961 - 1.060 |
| 52-Week Range | 0.563 - 2.720 |
| Beta | 1.61 |
| Analysts | Buy |
| Price Target | 3.17 (+204.81%) |
| Est. Earnings | Nov 9, 2026 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and i... [Read more]
Financial Performance
In 2025, Inovio Pharmaceuticals's revenue was $65,343, a decrease of -69.99% compared to the previous year's $217,756. Losses were -$84.95 million, -20.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for INO stock is "Buy." The 12-month stock price target is $3.17, which is an increase of 204.81% from the latest price.
News
Inovio Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
INO-3107 for RRP is nearing FDA approval with strong clinical data showing significant reductions in surgeries and broad patient benefit. Commercial launch preparations are underway, while the pipeline advances through partnerships and promising early-stage programs.
Inovio Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A proprietary DNA medicines platform is advancing toward potential approval with INO-3107 for RRP, showing strong efficacy and safety in reducing surgeries. Commercial preparations are underway, with a pivotal FDA decision expected October 30 and a robust pipeline and cash runway supporting future growth.
INOVIO to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
Inovio reports Q2 EPS (7c) vs. (61c) last year
INOVIO (INO) estimates that current cash, cash equivalents and short-term investments balances of $36.7M – excluding net proceeds from the July 2026 offering of approximately $18.3M – will support ope...
Inovio upgraded to Buy from Hold at Jefferies
Jefferies upgraded Inovio (INO) to Buy from Hold with a price target of $3, up from $1.80. After speaking with management, the firm is “incrementally positive” on the shares, saying…
Inovio Pharmaceuticals Earnings Call Transcript: Q2 2026
Regulatory review of INO-3107 is progressing, with FDA inspections complete and a PDUFA date set for October 30, 2026. Financials show reduced operating expenses and a strengthened cash position, supporting commercial launch preparations and pipeline development.
Inovio Pharmaceuticals Quarterly report: Q2 2026
Inovio Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 12, 2026.
Inovio Pharmaceuticals Earnings release: Q2 2026
Inovio Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Inovio Pharmaceuticals Slides: Q2 2026
Inovio Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Dr...
INOVIO to Report Second Quarter Financial Results on August 12, 2026
PLYMOUTH MEETING, Pa., Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
Inovio price target lowered to $4 from $6 at Piper Sandler
Piper Sandler lowered the firm’s price target on Inovio (INO) to $4 from $6 due to dilution from the recent financing. The firm keeps an Overweight rating on the shares.
INOVIO Announces Pricing of $20.0 Million Public Offering
PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
Inovio announces common stock and warrants offering, no amount given
Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public…
INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prote...
Inovio files $300M mixed securities shelf
16:03 EDT Inovio (INO) files $300M mixed securities shelf
Inovio Pharmaceuticals Registration statement: Registration filing
Inovio Pharmaceuticals filed a registration statement on July 2, 2026, providing details about a securities offering with the SEC.
Inovio Pharmaceuticals Slides: Corporate presentation
Inovio Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Inovio Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted INO-3107's potential to address unmet needs in RRP, with strong efficacy and safety data, a differentiated mechanism, and a patient-focused regimen. Regulatory review is ongoing, with commercial launch plans in place and a robust pipeline supporting future growth.
Inovio price target lowered to $2.50 from $3 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Inovio (INO) to $2.50 from $3 and keeps a Neutral rating on the shares post the Q1 report. The firm cites increasing…
INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
Inovio: ApolloBio announces ‘positive’ results from Phase 3 trial of VGX-3100
Inovio (INO) announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO’s investigational DNA immunotherapy bein...
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further high...
Inovio Pharmaceuticals Transcript: AGM 2026
Directors and key proposals were approved, with a focus on advancing INO-3107 toward FDA approval and commercial launch. Financial discipline reduced operating expenses, and partnerships are driving pipeline progress. Cash runway extends into Q1 2027.
Inovio Pharmaceuticals Earnings Call Transcript: Q1 2026
INO-3107 remains on track for its October 2026 PDUFA date, with FDA review progressing and no new issues raised. Financially, cash runway extends into Q1 2027 after a $16M equity raise, and commercial plans are advancing for a differentiated launch in a largely untapped RRP market.